| Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation F Ravandi, ML Alattar, MR Grunwald, MA Rudek, T Rajkhowa, MA Richie, ... Blood, The Journal of the American Society of Hematology 121 (23), 4655-4662, 2013 | 446 | 2013 |
| Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic … MA Sekeres, M Othus, AF List, O Odenike, RM Stone, SD Gore, MR Litzow, ... Journal of Clinical Oncology 35 (24), 2745-2753, 2017 | 241 | 2017 |
| TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups D Haase, KE Stevenson, D Neuberg, JP Maciejewski, A Nazha, ... Leukemia 33 (7), 1747-1758, 2019 | 227 | 2019 |
| Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes A Nazha, M Narkhede, T Radivoyevitch, DJ Seastone, BJ Patel, AT Gerds, ... Leukemia 30 (11), 2214-2220, 2016 | 172 | 2016 |
| Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome P Strati, H Kantarjian, F Ravandi, A Nazha, G Borthakur, N Daver, T Kadia, ... American journal of hematology 90 (4), 276-281, 2015 | 169 | 2015 |
| Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities P Jain, H Kantarjian, A Nazha, S O’Brien, E Jabbour, CG Romo, S Pierce, ... Blood, The Journal of the American Society of Hematology 121 (24), 4867-4874, 2013 | 169 | 2013 |
| hnRNP K is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies M Gallardo, HJ Lee, X Zhang, C Bueso-Ramos, LR Pageon, M McArthur, ... Cancer cell 28 (4), 486-499, 2015 | 145 | 2015 |
| Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer RJ Molenaar, S Sidana, T Radivoyevitch, AS Advani, AT Gerds, ... Journal of clinical oncology 36 (18), 1831-1839, 2018 | 140 | 2018 |
| An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies E Padron, G Garcia-Manero, MM Patnaik, R Itzykson, T Lasho, A Nazha, ... Blood cancer journal 5 (7), e333-e333, 2015 | 135 | 2015 |
| The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort M Stahl, M DeVeaux, T De Witte, J Neukirchen, MA Sekeres, AM Brunner, ... Blood advances 2 (14), 1765-1772, 2018 | 124 | 2018 |
| Measuring the symptom burden associated with the treatment of chronic myeloid leukemia LA Williams, AGG Gonzalez, P Ault, TR Mendoza, ML Sailors, JL Williams, ... Blood, The Journal of the American Society of Hematology 122 (5), 641-647, 2013 | 118 | 2013 |
| Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells F Pan, TS Wingo, Z Zhao, R Gao, H Makishima, G Qu, L Lin, M Yu, ... Nature communications 8 (1), 15102, 2017 | 117 | 2017 |
| Personalized prediction model to risk stratify patients with myelodysplastic syndromes A Nazha, R Komrokji, M Meggendorfer, X Jia, N Radakovich, J Shreve, ... Journal of Clinical Oncology 39 (33), 3737-3746, 2021 | 115 | 2021 |
| Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the International … R Bejar, E Papaemmanuil, T Haferlach, G Garcia-Manero, JP Maciejewski, ... Blood, The Journal of the American Society of Hematology 126 (23), 907-907, 2015 | 111 | 2015 |
| Machine learning in haematological malignancies N Radakovich, M Nagy, A Nazha The Lancet Haematology 7 (7), e541-e550, 2020 | 105 | 2020 |
| Genomic determinants of chronic myelomonocytic leukemia BJ Patel, B Przychodzen, S Thota, T Radivoyevitch, V Visconte, ... Leukemia 31 (12), 2815-2823, 2017 | 99 | 2017 |
| Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL) SR Sanikommu, MJ Clemente, P Chomczynski, MG Afable, A Jerez, ... Leukemia & lymphoma 59 (2), 416-422, 2018 | 94 | 2018 |
| EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single … E Jabbour, J Cortes, A Nazha, S O'Brien, A Quintas-Cardama, S Pierce, ... Blood, The Journal of the American Society of Hematology 119 (19), 4524-4526, 2012 | 86 | 2012 |
| Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts AM Zeidan, PC Boddu, MM Patnaik, JP Bewersdorf, M Stahl, RK Rampal, ... The Lancet Haematology 7 (8), e601-e612, 2020 | 77 | 2020 |
| Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) CD DiNardo, G Garcia‐Manero, S Pierce, A Nazha, C Bueso‐Ramos, ... American journal of hematology 91 (2), 227-232, 2016 | 73 | 2016 |
Mikkael SekeresProfessor of Medicine, Sylvester Comprehensive Cancer Center, University of Miami在 med.miami.edu 的电子邮件经过验证
